Micromem Technologies Inc.
Consolidated Financial Statements
For the years ended October 31, 2023, 2022 and 2021
(Expressed in United States Dollars)
Micromem Technologies Inc.
Consolidated Financial Statements
For the years ended October 31, 2023, 2022 and 2021
(Expressed in United States Dollars)
Contents
|
Report of Independent Registered Public Accounting Firm |
To the Board of Directors and Shareholders of Micromem Technologies Inc.
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated statements of financial position of Micromem Technologies Inc. (the "Company") as of October 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, changes in shareholders' deficiency, and cash flows for each of the years in the three-year period ended October 31, 2023, and the related notes (collectively referred to as the consolidated financial statements).
In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of October 31, 2023 and 2022, and the results of its consolidated operations and its consolidated cash flows for each of the years in the three-year period ended October 31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").
Material Uncertainty Related to Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring net losses and comprehensive losses, negative cash flows from operations and working capital deficiencies that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. This matter is also described in the "Critical Audit Matters" section of our report.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
MNP LLP | |
1 Adelaide Street East, Suite 1900, Toronto ON, M5C 2V9 | 1.877.251.2922 T: 416.596.1711 F: 416.596.7894 |
Going Concern
Critical Audit Matter Description
As described in Note 2, the Company's operations are mainly funded with debt financing, which is dependent upon many external factors and may be difficult to raise when required. The Company may not have sufficient cash to fund its operations, and therefore, will require additional funding, which if not raised, may result in the delay, postponement or curtailment of some or all of its activities. Management has prepared future cash flow forecasts, which involves judgement and estimation of key variables, such as planned capital expenditures, revenue, production volumes and market conditions. Future economic conditions and effects of key events subsequent to the year end, such as debt financing, also impacted management's judgements and estimates. We identified the Company's ability to continue as a going concern as a critical audit matter because auditing the Company's going concern assessment is complex and involves a high degree of auditor judgment to assess the reasonableness of the cash flow forecasts, planned refinancing actions and other assumptions used in the Company's going concern analysis. This matter is also described in the "Material Uncertainty Related to Going Concern" section of our report.
Audit Response
We responded to this matter by performing procedures over management's assessment of the Company's ability to continue as a going concern. Our audit work in relation to this included, but was not restricted to, the following:
- We evaluated the cash flow forecasts prepared by management and evaluated the integrity and arithmetical accuracy of the model.
- We evaluated the key assumptions used in the model to estimate future cash flows for a reasonable period of time, of at least 12 months from the date of the Statement of Financial Position, by comparing assumptions used by management against historical performance, budgets, economic and industry indicators and publicly available information.
- We evaluated the key assumptions pertaining to estimated cash flows from operating activities and expected cash flows from financing activities, comparing these to available market data, underlying agreements, private placement raises and subsequent events thereafter.
- We assessed the adequacy of the going concern disclosures included in Note 2 of the consolidated financial statements and consider these to appropriately reflect the assessments that management has performed.
Valuation of Financial Instruments
Critical Audit Matter Description
As described in Note 11 to the consolidated financial statements, for the year ended October 31, 2023, the Company has various convertible debentures some of which result in the recognition of derivative liabilities or equity components. Management measured the fair value of the embedded derivative liability and the fair value of host loans using valuation techniques that require management to make several assumptions related to the inputs into those models. Auditing management's fair value calculations was challenging due to the complexity of accounting for the instruments, the related valuation models and the inputs into those models, which are highly sensitive to changes, such as volatility, risk free rates, variable conversion price and discount rate.
Audit Response
We responded to this matter by performing procedures over valuation of debt instruments. Our audit work in relation to this included, but was not restricted to:
- We obtained and reviewed management's analysis of the financial instruments, including the assessment of the accounting for the financial instruments and the valuation methodology.
- We obtained signed copies of all agreements, including renewals, conversions and any new issuances and confirmed the balances and terms for a sample of the financial instruments.
- We obtained support for cash receipts related to a sample of newly issued financial instruments and cash disbursements related to a sample of repayments, and, for a sample of conversions, obtained support such as conversion notices and share issuances as confirmed with the transfer agent.
- We involved internal professionals with specialized skills and knowledge to assist in developing an independent implied interest rate range for a similar liability without a convertible feature and to assess the prepayment option embedded in the loans.
1 Adelaide Street East, Suite 1900, Toronto, Ontario, M5C 2V9 1.877.251.2922 T: 416.596.1711 F: 416.596.7894 MNP.ca | |
- We tested the mathematical accuracy of the valuation model and agreed certain inputs including volatility, risk free rates, variable conversion rates and discount rate to underlying source information.
| |
Toronto, Canada | Chartered Professional Accountants |
January 30, 2024 | Licensed Public Accountants |
| |
We have served as the Company's auditor since 2017 | |
| |
1 Adelaide Street East, Suite 1900, Toronto, Ontario, M5C 2V9 1.877.251.2922 T: 416.596.1711 F: 416.596.7894 MNP.ca | |
Micromem Technologies Inc.
Consolidated Statements of Financial Position
As at October 31, 2023 and October 31, 2022
(Expressed in United States dollars)
| | | | | | | | |
| Notes | | | As at October 31, 2023 | | | As at October 31, 2022 | |
| | | | | | | | |
Assets | | | | | | | | |
Current | | | | | | | | |
Cash | 20 | | $ | 31,584 | | $ | 33,227 | |
Prepaid expenses and other receivables | 19 (b), (d) | | | 103,999 | | | 18,200 | |
Total current assets | | | | 135,583 | | | 51,427 | |
Property and equipment | 6 | | | 32,767 | | | 48,092 | |
| | | | | | | | |
Total assets | | | $ | 168,350 | | $ | 99,519 | |
| | | | | | | | |
Liabilities | | | | | | | | |
Current | | | | | | | | |
Trade payables and other liabilities | 18(b), 20(d) | | $ | 209,285 | | $ | 287,575 | |
Deposit liability | 19 (d) | | | 63,000 | | | - | |
Current lease liability | 8 | | | 17,036 | | | 15,366 | |
Debenture payable | 10 | | | 37,509 | | | 38,001 | |
Convertible debentures | 11,20 | | | 3,548,059 | | | 3,792,064 | |
Derivative liabilities | 11,20 | | | 1,079,393 | | | 641,299 | |
Total current liabilities | | | | 4,954,282 | | | 4,774,305 | |
Non-current lease liability | 8 | | | 12,018 | | | 29,418 | |
Long-term loan | 9 | | | 43,254 | | | 43,796 | |
Total liabilities | | | | 5,009,554 | | | 4,847,519 | |
| | | | | | | | |
Shareholders' Deficiency | | | | | | | | |
Share capital | 12 | | | 90,471,712 | | | 87,784,725 | |
Contributed surplus | | | | 24,868,843 | | | 27,459,730 | |
Equity component of convertible debentures | 11 | | | 3,220,473 | | | 793,140 | |
Accumulated deficit | | | | (123,402,232 | ) | | (120,785,595 | ) |
Total shareholders' deficiency | | | | (4,841,204 | ) | | (4,748,000 | ) |
| | | | | | | | |
Total liabilities and shareholders' deficiency | | | $ | 168,350 | | $ | 99,519 | |
| | | | | | | | |
Going concern | 2 | | | | | | | |
Commitments and Contingencies | 19 | | | | | | | |
Subsequent events | 22 | | | | | | | |
The accompanying notes are an integral part of these consolidated financial statements.
Approved on behalf of the Board of Directors:
"Joseph Fuda" | | "Alex Dey" |
Director | | Director |
Micromem Technologies Inc.
Consolidated Statements of Operations and Comprehensive Loss
For the years ended October 31, 2023, 2022, and 2021
(Expressed in United States dollars)
| | | | | Years ended October 31, | |
| | Notes | | | 2023 | | | 2022 | | | 2021 | |
| | | | | | | | | | | | |
Operating expenses | | | | | | | | | | | | |
General and administrative | | 16(a) | | $ | 148,616 | | $ | 185,366 | | $ | 155,504 | |
Professional, other fees and salaries | | 16(b) | | | 610,052 | | | 647,710 | | | 424,485 | |
Statute barred payables | | 18(b) | | | - | | | - | | | (422,982 | ) |
Stock-based compensation | | 13 | | | 217,965 | | �� | 41,484 | | | 360,044 | |
Travel and entertainment | | | | | 63,360 | | | 59,504 | | | 24,903 | |
Depreciation of property and equipment | | 6 | | | 16,492 | | | 25,878 | | | 28,033 | |
Amortization of patents | | 7 | | | - | | | 3,877 | | | 8,000 | |
Foreign exchange (gain) loss | | | | | (62,613 | ) | | (176,477 | ) | | 222,553 | |
Total operating expenses | | | | | 993,872 | | | 787,342 | | | 800,540 | |
| | | | | | | | | | | | |
Other expenses (income) | | | | | | | | | | | | |
Accretion expense | | 11 | | | 279,834 | | | 1,179,603 | | | 1,169,921 | |
Interest expense on convertible debt | | 11 | | | 540,929 | | | 469,425 | | | 495,809 | |
Other finance expenses | | 11 | | | 86,352 | | | 13,233 | | | 84,478 | |
Gain on revaluation of derivative liabilities | | 11 | | | (658,503 | ) | | (409,607 | ) | | (2,547,192 | ) |
Loss (gain) on conversion of convertible debentures | | 11 | | | 21,120 | | | 94,326 | | | (9,506 | ) |
Loss (gain) on repayment of convertible debentures | | 11 | | | 27,243 | | | (47,877 | ) | | - | |
Loss on extinguishment of convertible debentures | | 11 | | | 1,400,823 | | | 200,650 | | | 1,018,928 | |
Total other expenses | | | | | 1,697,798 | | | 1,499,753 | | | 212,438 | |
| | | | | | | | | | | | |
Loss before income tax provision | | | | | (2,691,670 | ) | | (2,287,095 | ) | | (1,012,978 | ) |
Income tax provision | | 15 | | | - | | | - | | | - | |
Net loss and comprehensive loss | | | | $ | (2,691,670 | ) | $ | (2,287,095 | ) | $ | (1,012,978 | ) |
| | | | | | | | | | | | |
Weighted average number of outstanding shares, basic and diluted | | 14 | | | 490,310,376 | | | 451,177,796 | | | 422,613,046 | |
| | | | | | | | | | | | |
Loss per share, basic and diluted | | 14 | | $ | (0.01 | ) | $ | (0.01 | ) | $ | - | |
The accompanying notes are an integral part of these consolidated financial statements.
Micromem Technologies Inc.
Consolidated Statements of Changes in Shareholders' Deficiency
For the years ended October 31, 2023, 2022, and 2021
(Expressed in United States dollars)
| | Notes | | | Number of shares | | | Share capital | | | Contributed surplus | | | Equity component of convertible debentures | | | Accumulated deficit | | | Total | |
| | | | | | | | | | | | | | | | | | | | | |
Balance at November 1, 2020 | | | | | 402,552,453 | | $ | 85,463,642 | | $ | 27,810,586 | | $ | 23,952 | | $ | (117,485,522 | ) | $ | (4,187,342 | ) |
Private placements of shares for cash | | 12 | | | 17,573,429 | | | 840,564 | | | - | | | - | | | - | | | 840,564 | |
Convertible debentures converted into common shares | | 11 | | | 15,611,852 | | | 511,630 | | | - | | | - | | | - | | | 511,630 | |
Expiry of convertible debenture conversion option | | 11 | | | - | | | - | | | 26,752 | | | (26,752 | ) | | - | | | - | |
Renewal of convertible debentures | | 11 | | | - | | | - | | | - | | | 16,804 | | | - | | | 16,804 | |
Stock-based compensation | | 12 | | | - | | | - | | | 360,044 | | | - | | | - | | | 360,044 | |
Net loss and comprehensive loss | | | | | - | | | - | | | - | | | - | | | (1,012,978 | ) | | (1,012,978 | ) |
| | | | | | | | | | | | | | | | | | | | | |
Balance at October 31, 2021 | | | | | 435,737,734 | | $ | 86,815,836 | | $ | 28,197,382 | | $ | 14,004 | | $ | (118,498,500 | ) | $ | (3,471,278 | ) |
| | | | | | | | | | | | | | | | | | | | | |
Private placements of shares for cash | | 12 | | | 5,012,450 | | | 207,588 | | | - | | | - | | | - | | | 207,588 | |
Share issuance costs | | 12 | | | - | | | (25,591 | ) | | - | | | - | | | - | | | (25,591 | ) |
Convertible debentures converted into common shares | | 11 | | | 26,443,820 | | | 764,432 | | | - | | | - | | | - | | | 764,432 | |
Shares issued on settlement of accounts payable | | 12 | | | 413,674 | | | 22,460 | | | - | | | - | | | - | | | 22,460 | |
Expiry of convertible debenture conversion option | | 11 | | | - | | | - | | | 1,258,388 | | | (1,258,388 | ) | | - | | | - | |
Renewal of convertible debentures | | 11 | | | - | | | - | | | (2,037,524 | ) | | 2,037,524 | | | - | | | - | |
Stock-based compensation | | 13 | | | - | | | - | | | 41,484 | | | - | | | - | | | 41,484 | |
Net loss and comprehensive loss | | | | | - | | | - | | | - | | | - | | | (2,287,095 | ) | | (2,287,095 | ) |
Balance at October 31, 2022 | | | | | 467,607,678 | | $ | 87,784,725 | | $ | 27,459,730 | | $ | 793,140 | | $ | (120,785,595 | ) | $ | (4,748,000 | ) |
| | | | | | | | | | | | | | | | | | | | | |
Private placements of shares for cash | | 12 | | | 9,864,500 | | | 535,525 | | | - | | | - | | | - | | | 535,525 | |
Share issuance costs | | 12 | | | - | | | (25,586 | ) | | - | | | - | | | - | | | (25,586 | ) |
Convertible debentures converted into common shares | | 11 | | | 30,346,660 | | | 1,742,226 | | | - | | | (85,804 | ) | | - | | | 1,656,422 | |
Exercise of stock options | | 13 | | | 2,550,000 | | | 434,822 | | | (220,682 | ) | | - | | | - | | | 214,140 | |
Expiry of stock options | | | | | - | | | - | | | (75,033 | ) | | - | | | 75,033 | | | - | |
Expiry of convertible debenture conversion option | | 11 | | | - | | | - | | | 793,139 | | | (793,139 | ) | | - | | | - | |
Renewal of convertible debentures | | 11 | | | - | | | - | | | (3,306,276 | ) | | 3,306,276 | | | - | | | - | |
Stock-based compensation | | 13 | | | - | | | - | | | 217,965 | | | - | | | - | | | 217,965 | |
Net loss and comprehensive loss | | | | | - | | | - | | | - | | | - | | | (2,691,670 | ) | | (2,691,670 | ) |
Balance at October 31, 2023 | | | | | 510,368,838 | | $ | 90,471,712 | | $ | 24,868,843 | | $ | 3,220,473 | | $ | (123,402,232 | ) | $ | (4,841,204 | ) |
The accompanying notes are an integral part of these consolidated financial statements.
Micromem Technologies Inc.
Consolidated Statements of Cash Flows
For the years ended October 31, 2023, 2022, and 2021
(Expressed in United States dollars)
| | | | | Years ended October 31, | |
| | Notes | | | 2023 | | | 2022 | | | 2021 | |
Operating activities | | | | | | | | | | | | |
Net loss | | | | $ | (2,691,670 | ) | $ | (2,287,095 | ) | $ | (1,012,978 | ) |
Items not affecting cash: | | | | | | | | | | | | |
Statute barred payables | | | | | - | | | - | | | (422,982 | ) |
Depreciation of property and equipment | | 6 | | | 16,492 | | | 25,878 | | | 28,033 | |
Amortization of patents | | 7 | | | - | | | 3,877 | | | 8,000 | |
Accretion expense | | 11,17 | | | 279,834 | | | 1,179,603 | | | 1,169,921 | |
Accrued interest on convertible debentures | | 17 | | | 471,596 | | | 368,280 | | | 605,507 | |
Stock-based compensation | | 13 | | | 217,965 | | | 41,484 | | | 360,044 | |
Loss (gain) on conversion of convertible debentures | | 11,17 | | | 21,120 | | | 94,326 | | | (9,506 | ) |
Loss (gain) on repayment of convertible debentures | | 11,17 | | | 27,243 | | | (47,877 | ) | | - | |
Gain on revaluation of derivative liabilities | | 11,17 | | | (658,503 | ) | | (409,607 | ) | | (2,547,192 | ) |
Loss on extinguishment of convertible debentures | | 11,17 | | | 1,400,823 | | | 200,650 | | | 1,018,928 | |
Foreign exchange (gain) loss | | | | | (67,031 | ) | | (136,336 | ) | | 421,937 | |
| | | | | (982,131 | ) | | (966,817 | ) | | (380,288 | ) |
Net changes in non-cash working capital: | | | | | | | | | | | | |
(Increase) decrease in prepaid expenses and other receivables | | | | | (85,799 | ) | | 5,807 | | | 1,414 | |
Increase in deposit liability | | | | | 63,000 | | | - | | | - | |
Decrease in trade payables and other liabilities | | | | | (78,290 | ) | | (36,021 | ) | | (383,892 | ) |
Cash flows used in operating activities | | | | | (1,083,220 | ) | | (997,031 | ) | | (762,766 | ) |
| | | | | | | | | | | | |
Investing activity | | | | | | | | | | | | |
Purchase of property and equipment | | 6 | | | (2,044 | ) | | - | | | (5,271 | ) |
Cash flows used in investing activity | | | | | (2,044 | ) | | - | | | (5,271 | ) |
| | | | | | | | | | | | |
Financing activities | | | | | | | | | | | | |
Principal payments on lease liability | | 8 | | | (15,609 | ) | | (25,317 | ) | | (27,282 | ) |
Proceeds from long-term loan | | | | | - | | | - | | | 17,974 | |
Proceeds from private placements of shares | | 12 | | | 535,525 | | | 207,588 | | | 840,564 | |
Share issuance costs | | | | | (25,586 | ) | | (25,591 | ) | | - | |
Proceeds from the exercise of options | | 13 | | | 214,140 | | | - | | | - | |
Proceeds from issuance of convertible debentures | | 17 | | | 645,151 | | | 765,671 | | | 510,000 | |
Repayments of convertible debentures | | 17 | | | (270,000 | ) | | (63,490 | ) | | (593,301 | ) |
Cash flows provided by financing activities | | | | | 1,083,621 | | | 858,861 | | | 747,955 | |
Net change in cash | | | | | (1,643 | ) | | (138,170 | ) | | (20,082 | ) |
Cash - beginning of period | | | | | 33,227 | | | 171,397 | | | 191,479 | |
Cash - end of period | | | | $ | 31,584 | | $ | 33,227 | | $ | 171,397 | |
| | | | | | | | | | | | |
Supplemental cash flow information | | | | | | | | | | | | |
Interest paid (classified in operating activities) | | 11 | | $ | 64,679 | | $ | 88,465 | | $ | 87,266 | |
Interest converted (classified in operating activities) | | 11 | | $ | 238,859 | | $ | 12,680 | | $ | 196,964 | |
Interest paid on non-convertible debt (classified in operating activities) | | | | $ | 9,170 | | $ | 9,604 | | $ | 11,785 | |
Interest paid on lease liability (classified in operating activities) | | 8 | | $ | 3,323 | | $ | 3,629 | | $ | 9,160 | |
Carrying amount of convertible debentures converted into common shares | | 17 | | $ | 1,742,226 | | $ | 764,432 | | $ | 521,136 | |
Shares issued on settlement of accounts payable | | 12 | | $ | - | | $ | 22,460 | | $ | - | |
ROU asset and lease liability recognized | | 8 | | $ | - | | $ | 48,408 | | $ | - | |
The accompanying notes are an integral part of these consolidated financial statements.
1. Reporting entity and nature of business
Micromem Technologies Inc. ("Micromem" or the "Company") is incorporated under the laws of the Province of Ontario, Canada. Micromem is a publicly traded company with its head office located at 121 Richmond Street West, Suite 602, Toronto, Ontario, Canada. The Company's common shares are currently listed on the Canadian Securities Exchange under the trading symbol "MRM" and on the Over the Counter Venture Market under the
trading symbol "MMTIF".
The Company develops, based upon proprietary technology, customized sensor applications for companies (referred to as "Development Partners") operating internationally in various industry segments. The Company has not generated commercial revenues through October 31, 2023 and is devoting substantially all its efforts to securing commercial revenue opportunities.
2. Going concern
These consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.
There are material uncertainties related to conditions and events that cast substantial doubt about the Company's ability to continue as a going concern and ultimately on the appropriateness of the use of the accounting principles applicable to a going concern. During the year ended October 31, 2023, the Company reported a net loss and comprehensive loss of $2,691,670 (2022 - $2,287,095, 2021 - $1,012,978) and negative cash flow from operations of $1,083,220 (2022 - $997,031, 2021 - $762,766). The Company's working capital deficiency as at October 31, 2023 was $4,818,699 (October 31, 2022 - $4,722,878).
The Company's success depends on the profitable commercialization of its proprietary sensor technology. Based upon its current operating and financial plans, management of the Company believes that it will have sufficient access to financial resources to fund the Company's planned operations through fiscal 2024; however, the ability of the Company to continue as a going concern is dependent upon its ability to secure additional financing and/or to profitably commercialize its technology. There is no assurance that the Company will be successful in the profitable commercialization of its technology, or will be able to secure the necessary additional financing. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability
of the Company to continue as a going concern. If the going concern assumption was not appropriate for these consolidated financial statements then adjustments could be necessary to the carrying value of assets and liabilities, the reported expenses and the statement of financial position classifications used; in such cases, these adjustments could be material.
3. Basis of presentation
These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
These consolidated financial statements were authorized for issuance and release by the Company's Board of Directors on January 30, 2024.
(a) Basis of consolidation
These consolidated financial statements include the accounts of Micromem Technologies Inc. and its subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
The Company's wholly-owned subsidiaries include:
(i) | Inactive subsidiaries | | Domiciled in |
| Micromem Applied Sensors Technology Inc. ("MAST") | | United States |
| 707019 Canada Inc. | | Canada |
| Memtech International Inc. | | Bahamas |
| Memtech International (USA) Inc., Pageant Technologies (USA) Inc. | | United States |
| Pageant Technologies Inc., Micromem Holdings (Barbados) Inc. | | Barbados |
3. Basis of presentation (continued)
(b) Basis of measurement
These consolidated financial statements have been prepared on the historical cost basis, except for financial instruments designated at fair value through profit and loss which are measured at their fair value.
(c) Functional and presentation currency
These consolidated financial statements are presented in United States dollars ("USD"), which is the functional currency of the Company and all of its subsidiaries.
(d) Use of estimates and judgments
The preparation of these consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made as appropriate in the reporting period they become known. Items for which actual results may differ materially from these estimates are described in the following section.
(i) Fair value of options and conversion features
The Company makes estimates and utilizes assumptions in determining the fair value for stock options and conversion features based on the application of the Black-Scholes option pricing model or the binomial option pricing model, depending on the circumstances. These pricing models require management to make various assumptions and estimates that are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term, risk-free interest rate, and exercise price in the binomial option pricing model.
(ii) Useful lives and recoverability of long-lived assets
Long-lived assets consist of property and equipment and patents. Depreciation and amortization is dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements.
(iii) Income taxes
Income taxes and tax exposures recognized in the consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.
When the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future, based on cash flow forecasts. These forecasts are adjusted for certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.
(iv) Going concern assumption
The Company applies judgment in assessing whether material uncertainties exist that would cause doubt as to the whether the Company could continue as a going concern.
4. Summary of significant accounting policies
The principal accounting policies applied to the preparation of these consolidated financial statements are set out below:
(a) Foreign currency translation
These consolidated financial statements are presented in USD, which is the functional currency of the Company and all of its subsidiaries. At each reporting date, foreign currency denominated monetary assets and liabilities are translated at year-end exchange rates. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Income, expenses, and cash flows, are translated into USD using average exchange rates for the year. Exchange differences arising from operating transactions are recorded in operating profit or loss for the period; exchange differences related to financing transactions are recognized in finance income or directly in equity.
(b) Financial instruments
All financial instruments are initially recorded at fair value at the time they are entered into. The Company aggregates its financial instruments in accordance with IFRS 9, Financial Instruments, into classes based on their nature and characteristics. Management determines the classification when the instruments are initially recognized, which is normally the date of the transaction. The Company's accounting policy for each class of financial instruments is as follows:
(i) Amortized cost
This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the solely principal and interest ("SPPI") criterion, and financial liabilities which are not required, and for which the Company has not elected to subsequently record at fair value through profit or loss.
Financial instruments in this category are initially recognized at fair value plus directly attributable transaction costs. Subsequently, these instruments are measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial instrument and of allocating interest over the relevant period. The effective interest rate is the rate that discounts estimated future cash receipts through the expected life of the financial instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Financial assets are adjusted for any expected credit losses (“ECLs”).
Financial assets in this category include cash and other receivables. Financial liabilities in this category include trade payables and other liabilities, debenture payable, convertible debentures and long-term loan.
(ii) Fair value through profit or loss ("FVTPL")
This category includes derivative instruments and debt instruments whose cash flow characteristics fail the SPPI criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. These financial instruments are initially recognized at fair value; all transaction costs are recognized immediately in profit or loss. Subsequently, these instruments are recognized at fair value at each reporting date. Any changes in fair value, and gains or losses upon disposition of the financial instruments are recognized in profit or loss. Financial liabilities in this category include the derivative liabilities.
(iii) Fair value through other comprehensive income ("FVOCI")
This category only includes equity instruments, which the Company intends to hold for the foreseeable future and which the Company has irrevocably elected to so classify upon initial recognition or transition. Equity instruments in this category are subsequently measured at fair value with changes recognized in other comprehensive income, with no recycling of gains or losses to profit or loss upon derecognition. Dividend income is recognized in earnings. Equity instruments at FVOCI are not subject to an impairment assessment under IFRS 9. The Company has no financial assets in this category.
(c) Convertible debentures and derivative liabilities
The Company issues convertible debentures used as bridge loans, which can be converted into common shares at the option of the holder, into a fixed number of shares for a fixed amount of consideration, or into a fixed number of shares for a variable amount of consideration, or into a variable number of shares.
4. Summary of significant accounting policies (continued)
(c) Convertible debentures and derivative liabilities (continued)
(i) Initial recognition
For convertible debentures which provide conversion into a fixed number of shares, the liability component is recognized initially at the fair value of a similar, non-convertible liability. The equity component is recognized as the difference between the fair value of the instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.
For convertible debentures which provide conversion into a variable number of shares or into a fixed number of shares for a variable amount of consideration, the conversion option is accounted for as an embedded derivative, which is separated from the host contract. Upon initial recognition, the derivative liability is valued at fair value using a Black Scholes or a binomial pricing model. The carrying amount of the convertible debenture is recognized as the difference between the fair value of the instrument as a whole and the fair value of the derivative liability. Any directly attributable transaction costs are allocated to the derivative liability and host contract in proportion to their initial carrying amounts.
(ii) Modifications and extinguishments
To the extent there are changes to the terms of outstanding convertible debentures, these changes may be recorded as a modification or an extinguishment. A substantial change in the terms of an existing financial liability is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The terms are substantially different if the discounted present value of the cash flows at the original effective interest rate under the new terms is at least 10% different from the discounted present value of the remaining cash flows of the original financial liability. For a modification that does not result in derecognition, a gain or loss will be recognised in profit or loss for the difference between the original contractual cash flows and the modified cash flows discounted at the original effective interest rate. For a modification that results in derecognition, a gain or loss will be recognised in profit or loss for the difference between the carrying amount of the financial liability extinguished and the fair value of the modified financial liability.
(d) Fair value
Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.
Fair value measurement for financial instruments are categorized into levels within a fair value hierarchy based on the nature of the valuation inputs (Levels 1, 2 or 3). The three levels are defined based on the observability of significant inputs to the measurement, as follows:
Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities. There are no assets or liabilities in this category in these consolidated financial statements.
Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. In these consolidated financial statements, derivative liabilities are included in this category.
Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data. There are no assets or liabilities in this category in these consolidated financial statements.
When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument.
A market is regarded as “active” if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction.
The derivative liabilities are measured at fair value on a recurring basis and categorized as level 2 in the fair value hierachy. The fair value of the derivative liabilities at October 31, 2023 is $1,079,393 (2022 - $641,299). See Note 11 (c).
The Company's policy for determining when transfers between levels of fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer. During the years ended October 31, 2023 and 2022, there were no transfers between levels.
4. Summary of significant accounting policies (continued)
(e) Property and equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives at the following annual rates and methods:
| | | Method | | Rate |
| | Computers | Declining balance | | 30% |
| | Right-of-use asset | Straight-line | | lesser of useful life and lease term (three years) |
(f) Impairment of long-lived assets
The Company follows the guidelines prescribed in IAS 36, Impairment of Assets with respect to the measurement for impairment of assets. The carrying amounts of property and equipment and patents are reviewed for impairment when events or changes in circumstances indicate that the carrying amounts may not be recoverable. When the carrying amount exceeds the estimated recoverable amount, the assets are written down to their recoverable amount. The recoverable amount of long-lived assets is the greater of fair value less costs to sell and value in use. Impairment losses are recognized in the consolidated statements of operations and comprehensive loss.
(g) Development costs
Research costs are expensed in the period incurred. Development costs are expensed as incurred unless they meet the criteria for capitalization. Expenditures during the development phase are capitalized if the Company can demonstrate each of the following criteria: (i) the technical feasibility of completing the asset so that it will be available for use or sale, (ii) its intention to complete the asset and use or sell it, (iii) its ability to use or sell the asset, (iv) how the asset will generate probable future economic benefits, (v) the availability of adequate technical, financial and other resources to complete the development and to use or sell the asset, and (vi) its ability to measure reliably the expenditure attributable to the asset during its development; otherwise, these costs are expensed as incurred. Costs to be recovered from development partners are recorded to development costs receivable. Payments received from development partners on projects are recorded to income as a recovery of costs incurred and reduce the outstanding receivable. There were no development costs incurred or recovery of such costs in 2023, 2022, or 2021.
(h) Patents
Patents are recorded at cost and are amortized on a straight line basis over their estimated useful lives of 5 years.
(i) Leases
As a lessee
At the inception of a contract, the Company assesses whether a contract is, or contains a lease. A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease.
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property and equipment.
The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate currently set at 9%. The lease liability is subsequently measured at amortized cost using the effective interest method.
The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value as there are none. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.
As a lessor
As a lessor, the Company classifies its leases as either a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease.
Rental income arising from operating leases is accounted on a straight-line basis over the lease term.
4. Summary of significant accounting policies (continued)
(j) Stock-based compensation and other stock-based payments
Where equity instruments are granted to employees, they are recorded at the fair value of the equity instrument granted at the grant date. The grant date fair value is recognized in net income over the vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received. When the value of goods or services received in exchange for the stock-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The cost recognized for all equity-settled stock-based payments is reflected in contributed surplus, until the instruments are exercised. Upon exercise, shares are issued from treasury and the amount previously reflected in contributed surplus along with any proceeds paid upon exercise, are credited to share capital.
(k) Government grants
The Company recognises government grants when there is reasonable assurance of compliance with grant conditions and that the grants will be received. Government grants are recognised in profit or loss on a systematic basis over the periods when the related expenses are incurred and are presented in the consolidated financial statements as a reduction of these expenses. A government grant that becomes receivable as compensation for expenses already incurred is recognised in profit or loss of the period in which it becomes receivable.
(l) Provisions
Provision for risks and expenses are recognized for probable outflows of resources that can be estimated and that result from present obligations resulting from past events. In the case where a potential obligation resulting from past events exists, but where occurrence of the outflow of resources is not probable or the estimate is not reliable, these contingencies are disclosed. Provisions, if any, are measured based on management's best estimates of outcomes on the basis of facts known at the reporting date.
(m) Income taxes
The Company accounts for its income taxes using the deferred tax assets and liabilities method. Deferred income tax assets and liabilities are determined based on the difference between the carrying amount and the tax basis of the assets and liabilities. Any change in the net amount of deferred income tax assets and liabilities is included in profit or loss or equity. Deferred income tax assets and liabilities are determined based on enacted or substantively enacted tax rates and laws which are expected to apply to taxable profit for the years in which the assets and liabilities will be recovered or settled. Deferred income tax assets are recognized when it is probable they will be realized. Deferred tax assets and liabilities are not discounted.
(n) Share capital
Share capital is presented at the fair value of the shares issued or the cash amount received. Costs related to the issuance of shares are reported in equity, net of tax, as a deduction from the issuance proceeds.
(o) Earnings or loss per share
The Company presents basic and diluted earnings per share data for its common shares. Basic earnings per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, for the effects of all potentially dilutive common shares, which comprise stock options and convertible debentures.
5. New accounting standards and pronouncements
(a) Amendment to IAS 1, Presentation of Financial Statements, Issued but not yet effective
IAS 1 was amended in January 2020 to address inconsistences with how entities apply the standard over classification of current and non-current liabilities. The amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should be classified as current or non-current. The amendment is effective for annual reporting periods beginning on or after January 1, 2024. Earlier adoption is permitted. The Company will adopt this amendment as of the effective date, and does not anticipate any material impacts on adoption.
5. New accounting standards and pronouncements (continued)
(b) Amendment to IAS 1, Presentation of Financial Statements, Issued but not yet effective
In February 2021, the IASB issued ‘Disclosure of Accounting Policies’ with amendments that are intended to help preparers in deciding which accounting policies to disclose in their financial statements. The amendments are effective for year ends beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt this amendment as of the effective date, and does not anticipate any material impacts on adoption.
(c) Amendment to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction, Issued but not yet effective
The amendment narrowed the scope of certain recognition exemptions so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. An entity applies the amendments to transactions that occur on or after the beginning of the earliest comparative period presented. It also, at the beginning of the earliest comparative period presented, recognizes deferred tax for all temporary differences related to leases and decommissioning obligations and recognizes the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at that date. The amendment is effective for annual periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and does not anticipate any material impacts on adoption.
(d) Amendment to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors, Issued but not yet effective
In February 2021, the IASB issued ‘Definition of Accounting Estimates’ to help entities distinguish between accounting policies and accounting estimates. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and is currently assessing the impacts of adoption.
(e) Amendment to IFRS 10, Consolidated Financial Statements and IAS 28, Investments in Associates and Joint Ventures, Issued but not yet effective
The amendment addresses a conflict between the requirements of IAS 28 and IFRS 10 and clarifies that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted. The Company will adopt the amendment as of the effective date, and does not anticipate any material impacts on adoption.
6. Property and equipment
| | As at November 1, 2022 | | | Additions | | | Disposals | | | Foreign exchange | | | As at October 31, 2023 | |
Cost | | | | | | | | | | | | | | | |
Computers | $ | 7,466 | | $ | 2,044 | | $ | - | | $ | - | | $ | 9,510 | |
Right-of-use assets | | 48,408 | | | - | | | - | | | - | | | 48,408 | |
| | 55,874 | | | 2,044 | | | - | | | - | | | 57,918 | |
Accumulated depreciation | | | | | | | | | | | | | | | |
Computers | | 3,748 | | | 1,148 | | $ | - | | $ | 85 | | $ | 4,981 | |
Right-of-use assets | | 4,034 | | | 15,344 | | | - | | | 792 | | | 20,170 | |
| | 7,782 | | | 16,492 | | | - | | | 877 | | | 25,151 | |
Net book value | $ | 48,092 | | | | | | | | | | | $ | 32,767 | |
6. Property and equipment (continued)
| | As at November 1, 2021 | | | Additions | | | Disposals | | | Foreign exchange | | | As at October 31, 2022 | |
Cost | | | | | | | | | | | | | | | |
Computers | $ | 18,570 | | $ | - | | $ | (11,104 | ) | $ | - | | $ | 7,466 | |
Right-of-use assets | | 74,307 | | | 48,408 | | | (74,307 | ) | | - | | | 48,408 | |
| | 92,877 | | | 48,408 | | | (85,411 | ) | | - | | | 55,874 | |
Accumulated depreciation | | | | | | | | | | | | | | | |
Computers | | 12,824 | | | 1,723 | | | (10,799 | ) | | - | | | 3,748 | |
Right-of-use assets | | 54,041 | | | 24,155 | | | (74,162 | ) | | - | | | 4,034 | |
| | 66,865 | | | 25,878 | | | (84,961 | ) | | - | | | 7,782 | |
Net book value | $ | 26,012 | | | | | | | | | | | $ | 48,092 | |
During the year ended October 31, 2022, the Company's lease agreement pertaining to the right-of-use asset as at October 31, 2021 expired and the asset was fully depreciated and derecognized. A new lease agreement was entered into and is therefore recorded as an addition during the year ended October 31, 2022. Refer to Note 8.
7. Patents
| | As at November 1, | | | | | | | | | As at October 31, | |
| | 2022 | | | Additions | | | Disposals | | | 2023 | |
Cost | $ | 681,288 | | $ | - | | $ | - | | $ | 681,288 | |
Accumulated amortization | | 681,288 | | | - | | | - | | | 681,288 | |
Net book value | $ | - | | $ | - | | $ | - | | $ | - | |
| | | | | | | | | | | | |
| | As at November 1, | | | | | | | | | As at October 31, | |
| | 2021 | | | Additions | | | Disposals | | | 2022 | |
Cost | $ | 681,288 | | $ | - | | $ | - | | $ | 681,288 | |
Accumulated amortization | | 677,411 | | | 3,877 | | | - | | | 681,288 | |
Net book value | $ | 3,877 | | $ | (3,877 | ) | $ | - | | $ | - | |
The Company holds several patents in the United States for its Multimodal Fluid Condition Sensor Platform. The patents are fully amortized as at October 31, 2023 and 2022.
8. Leases
(a) As a lessee
The lease obligation relates to the use of office space in Toronto, Ontario. The lease agreement in effect for the year ended October 31, 2021 was set to expire on July 31, 2022. On May 26, 2022, a new lease agreement was entered into for a term from August 1, 2022 to July 31, 2025 for office space in another location in Toronto, Ontario. The present value of the lease obligation was calculated using a discount rate of 9%.
8. Leases (continued)
(a) As a lessee
The lease liability is summarized as follows:
Balance, October 31, 2020 | $ | 52,070 | |
Interest expense | | 9,160 | |
Lease payments | | (36,442 | ) |
Balance, October 31, 2021 | $
| 24,788 | |
New lease agreement | | 48,408 | |
Interest expense | | 3,629 | |
Lease payments | | (28,946 | ) |
Foreign exchange | | (3,095 | ) |
Balance, October 31, 2022 | | 44,784 | |
Interest expense | | 3,323 | |
Lease payments | | (18,932 | ) |
Foreign exchange | | (121 | ) |
Balance, October 31, 2023 | $ | 29,054 | |
The following represents a maturity analysis of the Company's undiscounted contractual lease obligations as at October 31, 2023:
| | | |
| | USD | |
Less than one year | $ | 18,822 | |
Between one and five years | $ | 12,756 | |
(b) As a lessor
The Company sub-leases a portion of its office space under a lease agreement for a term of three years, expiring July 31, 2025. The sub-lease is classified as an operating lease because it does not transfer substantially all of the risks and rewards incidental to ownership of the asset.
For the year ended October 31, 2023, the Company recognized a total of $17,682 (2022 - $19,076) as rental income which has been recorded as a reduction to general and administrative expenses on the consolidated statement of operations and comprehensive loss.
The following represents a maturity analysis of the Company's lease payments to be received after October 31, 2023:
| | | |
| | USD | |
Less than one year | $ | 17,626 | |
Between one and five years | $ | 14,593 | |
9. Long-term loan
The Company was granted a $60,000 CAD ($43,254 USD) interest-free loan from the Government of Canada under the Canada Emergency Business Account ("CEBA") program to cover its operating costs (the "CEBA Loan"). If the Company repays $40,000 CAD ($28,836 USD) of the aggregate amount advanced on or before January 18, 2024, the repayment of the remaining $20,000 CAD will be forgiven. The balance was not paid by January 18, 2024, and as a result, the total principal amount was subsequently converted to a 3-year term loan at 5% annual interest paid monthly, commencing January 19, 2024. The total amount owing on the CEBA loan as at October 31, 2023 is $43,254 ($60,000 CAD) (October 31, 2022 - $43,796 ($60,000 CAD)).
10. Debenture payable
The Company issued a debenture on March 17, 2020, with a principal amount of $51,500 CAD ($37,126 USD) and an original maturity date of June 17, 2020. The debenture's maturity date was extended by six month intervals on June 17, 2020, December 17, 2020, June 17, 2021, December 17, 2021, June 17, 2022, December 17, 2022 and June 17, 2023. The most recent extension on June 17, 2023 extended the debenture to December 17, 2023. The extension of the debenture's maturity date resulted in a substantial modification of the existing terms of the debenture and accordingly was accounted for as an extinguishment. The debenture bears interest at a rate of 24% and is unsecured. At October 31, 2023, the debenture had an outstanding balance of $37,509 ($52,031 CAD) (October 31, 2022 - $38,001 ($52,062 CAD)). During the year ended October 31, 2023, total interest expense of $9,170 (2022 - $9,604, 2021 - $7,261) was recognized in the consolidated statement of operations and comprehensive loss.
11. Convertible debentures
The Company issues three types of convertible debentures: USD denominated convertible debentures with an equity component, Canadian dollar ("CAD") denominated convertible debentures with an embedded derivative due to variable consideration payable upon conversion caused by foreign exchange, and USD denominated convertible debentures with an embedded derivative caused by variable conversion prices.
During the year ended October 31, 2023, the Company incurred $86,352 of financing costs (2022 - $21,000, 2021 - $84,478) which primarily consisted of early repayment and administrative fees, of which $nil (2022 - $nil, 2021 - $nil) was converted into common shares.
(a) Current period information presented in the consolidated financial statements
Convertible debentures outstanding as at October 31, 2023:
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Loan principal outstanding | $ | 1,261,265 | | $ | 2,146,715 | | $ | 405,001 | | | | |
| | | |
Terms of loan | | | | | | | | | | | | |
Annual stated interest rate | | 24% | | | 12% - 24% | | | 2% - 4% | | | | |
Effective annual interest rate | | 24% | | | 22 - 131% | | | 24% - 5158% | | | | |
Conversion price to common shares | $ | 0.03 - $0.04 | | $ | 0.05 - $0.10 | | | (i) - (ii) | | | | |
Remaining life (in months) | | 0 - 4 | | | 0 - 11 | | | 0 - 11 | | | | |
| | | |
Consolidated Statement of Financial Position | | | | | | | | | | | | |
Carrying value of loan principal | $ | 1,261,265 | | $ | 1,499,667 | | $ | 77,238 | | $ | 2,838,170 | |
Interest payable | | 344,993 | | | 334,511 | | | 30,385 | | | 709,889 | |
Convertible debentures | $ | 1,606,258 | | $ | 1,834,178 | | $ | 107,623 | | $ | 3,548,059 | |
| | | | | | | | | | | | |
Derivative liabilities | $ | - | | $ | 783,650 | | $ | 295,743 | | $ | 1,079,393 | |
Equity component of convertible debentures | $ | 3,220,473 | | $ | - | | $ | - | | $ | 3,220,473 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
For the year ended October 31, 2023: | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Consolidated Statement of Operations and Comprehensive Loss | | | | | | | | | | | | |
Accretion expense | $ | 18,258 | | $ | 243,162 | | $ | 18,414 | | $ | 279,834 | |
Interest expense | $ | 273,458 | | $ | 254,523 | | $ | 12,948 | | $ | 540,929 | |
Gain on revaluation of derivative liabilities | $ | - | | $ | (507,186 | ) | $ | (151,317 | ) | $ | (658,503 | ) |
Loss on conversion of convertible debentures | $ | - | | $ | - | | $ | 21,120 | | $ | 21,120 | |
Loss on repayment of convertible debentures | $ | - | | $ | - | | $ | 27,243 | | $ | 27,243 | |
(Gain) loss on extinguishment of convertible debentures | $ | 33,488 | | $ | 1,169,800 | | $ | 197,535 | | $ | 1,400,823 | |
| | | |
Consolidated Statement of Changes in Equity | | | | | | | | | | | | |
Amount of principal converted to common shares | $ | 250,000 | | $ | 455,000 | | $ | 232,700 | | | | |
Amount of interest converted to common shares | $ | 30,016 | | $ | 204,189 | | $ | 4,654 | | | | |
| | | | | | | | | | | | |
Number of common shares issued on conversion of convertible debentures | | 6,406,250 | | | 14,391,709 | | | 9,548,701 | | | 30,346,660 | |
11. Convertible debentures (continued)
(a) Current period information presented in the consolidated financial statements
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Consolidated Statement of Cash Flows | | | | | | | | | | | | |
Amount of principal repaid in cash | $ | - | | $ | - | | $ | 270,000 | | $ | 270,000 | |
Amount of interest repaid in cash | $ | 12,973 | | $ | 47,353 | | $ | 4,353 | | $ | 64,679 | |
(i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.
(ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.
(b) Comparative information presented in the consolidated financial statements
Convertible debentures outstanding as at October 31, 2022:
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Loan principal outstanding | $ | 1,205,144 | | $ | 2,321,755 | | $ | 347,700 | | | | |
| | | |
Terms of loan | | | | | | | | | | | | |
Annual stated interest rate | | 12% - 24% | | | 12% - 24% | | | 2% - 4% | | | | |
Effective annual interest rate | | 24% | | | 22 - 131% | | | 24% - 5803% | | | | |
Conversion price to common shares | | $0.03 - $0.07 | | | $0.05 - $0.08 | | | (i) - (ii) | | | | |
Remaining life (in months) | | 0 - 6 | | | 0 - 10 | | | 0 - 11 | | | | |
| | | |
Consolidated Statement of Financial Position | | | | | | | | | | | | |
Carrying value of loan principal | $ | 1,203,478 | | $ | 1,661,742 | | $ | 130,424 | | $ | 2,995,644 | |
Interest payable | | 380,360 | | | 389,617 | | | 26,443 | | | 796,420 | |
Convertible debentures | $ | 1,583,838 | | $ | 2,051,359 | | $ | 156,867 | | $ | 3,792,064 | |
| | | | | | | | | | | | |
Derivative liabilities | $ | - | | $ | 439,194 | | $ | 202,105 | | $ | 641,299 | |
Equity component of convertible debentures | $ | 793,140 | | $ | - | | $ | - | | $ | 793,140 | |
(i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.
(ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.
For the year ended October 31, 2022:
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Consolidated Statement of Operations and Comprehensive Loss | | | | | | | | | | |
Accretion expense | $ | 28,000 | | $ | 1,086,385 | | $ | 65,218 | | $ | 1,179,603 | |
Interest expense | $ | 230,058 | | $ | 232,211 | | $ | 7,156 | | $ | 469,425 | |
Gain on revaluation of derivative liabilities | $ | - | | $ | (379,736 | ) | $ | (29,871 | ) | $ | (409,607 | ) |
Loss on conversion of convertible debentures | $ | - | | $ | - | | $ | 94,326 | | $ | 94,326 | |
Gain on repayment of convertible debentures | $ | - | | $ | (661 | ) | $ | (47,216 | ) | $ | (47,877 | ) |
(Gain) loss on extinguishment of convertible debentures | $ | (28,007 | ) | $ | 99,078 | | $ | 129,579 | | $ | 200,650 | |
11. Convertible debentures (continued)
(b) Comparative information presented in the consolidated financial statements
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Consolidated Statement of Changes in Equity | | | | | | | | | | | | |
Amount of principal converted to common shares | $ | - | | $ | - | | $ | 712,100 | | | | |
Amount of interest converted to common shares | $ | - | | $ | - | | $ | 12,680 | | | | |
| | | |
Number of common shares issued on conversion of convertible debentures | | - | | | - | | | 26,443,820 | | | 26,443,820 | |
| | | | | | | | | | | | |
Consolidated Statement of Cash Flows | | | | | | | | | | | | |
Amount of principal repaid in cash | $ | - | | $ | 7,490 | | $ | 56,000 | | $ | 63,490 | |
Amount of interest repaid in cash | $ | 14,941 | | $ | 73,524 | | $ | - | | $ | 88,465 | |
| | | |
For the year ended October 31, 2021: | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | USD (equity component) | | | CAD (embedded derivative) | | | USD (embedded derivative) | | | Total | |
Consolidated Statement of Operations and Comprehensive Loss | | | | | | | | | | | | |
Accretion expense | $ | 28,001 | | $ | 1,003,613 | | $ | 138,307 | | $ | 1,169,921 | |
Interest expense | $ | 236,519 | | $ | 226,520 | | $ | 32,770 | | $ | 495,809 | |
(Gain) loss on revaluation of derivative liabilities | $ | - | | $ | (2,718,409 | ) | $ | 171,217 | | $ | (2,547,192 | ) |
(Gain) loss on conversion of convertible debentures | $ | - | | $ | (47,356 | ) | $ | 37,850 | | $ | (9,506 | ) |
(Gain) loss on extinguishment of convertible debentures | $ | - | | $ | 1,360,536 | | $ | (341,608 | ) | $ | 1,018,928 | |
| | | |
Consolidated Statement of Changes in Equity | | | | | | | | | | | | |
Amount of principal converted to common shares | $ | - | | $ | 100,000 | | $ | 284,000 | | | | |
Amount of interest converted to common shares | $ | 30,200 | | $ | 160,064 | | $ | 6,700 | | | | |
| | | |
Number of common shares issued on conversion of convertible debentures | | 1,118,519 | | | 7,744,774 | | | 6,748,559 | | | 15,611,852 | |
| | | |
Consolidated Statement of Cash Flows | | | | | | | | | | | | |
Amount of principal repaid in cash | $ | 205,100 | | $ | 31,492 | | $ | 364,370 | | $ | 600,962 | |
Amount of interest repaid in cash | $ | 25,101 | | $ | 36,052 | | $ | 26,113 | | $ | 87,266 | |
(c) Fair value of derivative liabilities outstanding
The fair value of the derivative liabilities is determined in accordance with the Black-Scholes or binomial option-pricing models, depending on the circumstances. The underlying assumptions are as follows:
| As at October 31, | | As at October 31, |
| 2023 | | 2022 |
Share price | $0.05 | | $0.03 |
Exercise price | $0.03 - $0.07 | | $0.02 - $0.07 |
Volatility factor (based on historical volatility) | 114% - 189% | | 140% - 232% |
Risk free interest rate | 5.11% - 5.48% | | 3.09% - 4.28% |
Expected life of conversion features (in months) | 0 - 11 | | 0 - 11 |
Expected dividend yield | 0% | | 0% |
CDN to USD exchange rate (as applicable) | 0.7209 | | 0.7299 |
Call value | $0.01 - $0.08 | | $0.00 - $0.02 |
The key unobservable input in these models relates to volatility. Volatility was estimated using the historical volatility of the Company's stock prices for common shares. Changes in these assumptions may affect the fair value estimates of the derivative liabilities.
12. Share capital
(a) Authorized and outstanding shares
The Company has two classes of shares as follows:
(i) Special redeemable voting preference shares - 2,000,000 authorized, nil issued and outstanding.
(ii) Common shares without par value – an unlimited number authorized. The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at shareholder meetings of the Company. All common shares are ranked equally with regards to the Company's residual assets.
(b) Private placements
(i) In 2023, the Company completed 26 private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $509,939 and issued a total of 9,864,500 common shares.
(ii) In 2022, the Company completed 9 private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $181,997 and issued a total of 5,012,450 common shares.
(iii) In 2021, the Company completed 37 private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $840,564 and issued a total of 17,573,429 common shares.
(c) Accounts payable settled in common shares
During the year ended October 31, 2023, $nil (2022 - $22,460, 2021 - $nil) of accounts payable was settled in exchange for nil (2022 - 413,674, 2021 - nil) common shares. There was no gain or loss recognized upon settlement.
13. Stock options
(a) Stock option plan
Under the Company’s fixed stock option plan (the “Plan”), the Company could grant up to 27,500,000 shares of common stock to directors, officers, employees or consultants of the Company and its subsidiaries. The exercise price of each option is equal to or greater than the market price of the Company's shares on the date of grant unless otherwise permitted by applicable securities regulations. An option's maximum term under the Plan is 10 years. Stock options are fully vested upon issuance by the Company unless the Board of Directors stipulates otherwise by Directors' resolution.
(b) Summary of changes
| | Number of options | | | Weighted average exercise price | |
Outstanding at October 31, 2020 | | 2,200,000 | | $ | 0.10 | |
Granted | | 9,500,000 | | | 0.06 | |
Outstanding at October 31, 2021 | | 11,700,000 | | $ | 0.06 | |
Granted | | 2,025,000 | | | 0.07 | |
Expired | | (2,000,000 | ) | | 0.07 | |
Outstanding at October 31, 2022 | | 11,725,000 | | $ | 0.06 | |
Granted | | 3,000,000 | | | 0.09 | |
Expired | | (2,400,000 | ) | | 0.08 | |
Exercised (i) | | (2,550,000 | ) | | 0.09 | |
Outstanding at October 31, 2023 | | 9,775,000 | | $ | 0.06 | |
(i) During the year ended October 31, 2023, the Company issued a total of 2,550,000 common shares related to the exercise of stock options for gross proceeds of $214,140.
13. Stock options (continued)
(c) Stock options outstanding at October 31, 2023
There were 3,000,000 options issued to directors, officers, employees and consultants during the year ended October 31, 2023 (2022 - nil, 2021 - 9,500,000 options issued). Of the 3,000,000 options granted, 2,750,000 options have vested, the remaining 250,000 options vested on January 6, 2024.
| | | | | | | | Weighted average | |
Date of issue | | Expiry date | | | Number of options | | | Exercise price | | | Remaining contractual life | |
November 13, 2020 | | November 13, 2025 | | | 5,750,000 | | $ | 0.05 | | | 2.0 | |
October 8, 2021 | | October 8, 2026 | | | 1,000,000 | | | 0.07 | | | 2.9 | |
December 15, 2021 | | December 15, 2023 | | | 25,000 | | | 0.07 | | | 0.1 | |
March 20, 2023 | | March 20, 2028 | | | 2,000,000 | | | 0.07 | | | 4.4 | |
April 6, 2023 | | April 6, 2024 | | | 1,000,000 | | | 0.12 | | | 0.4 | |
Outstanding at October 31, 2023 | | | 9,775,000 | | $ | 0.06 | | | 2.4 | |
Of the total options outstanding, 9,525,000 are exercisable as at October 31, 2023 (2022 - 10,225,000).
(d) Fair value of options issued during the year
The fair value of the stock options issued has been determined in accordance with the Black Scholes option-pricing model. Volatility was estimated using the historical volatility of the Company's stock prices for its common shares. The underlying assumptions are as follows:
| 2023 | | 2022 | | 2021 |
Share price at grant date | $0.07 - $0.12 | | $0.03 - $0.05 | | $0.05 |
Exercise price | $0.07 - $0.12 | | $0.07 | | $0.05 - 0.07 |
Volatility factor | 175% - 184% | | 212% - 272% | | 148% - 180% |
Risk free interest rate | 2.79% - 3.58% | | 0.97% - 4.33% | | 0.75% |
Expected life of options in years | 1 - 5 | | 1 - 2 | | 5 |
Expected divided yield | 0% | | 0% | | 0% |
Forfeiture rate | 0% | | 0% | | 0% |
Weighted average Black Scholes value at grant date | $0.06 - $0.08 | | $0.02 - $0.03 | | $0.05 - $0.06 |
During the year ended October 31, 2023, the Company recorded an expense of $217,965 related to the vesting of stock options (2022 - $41,484, 2021 - $360,044).
14. Loss per share
Basic and diluted loss per share are calculated using the following numerators and denominators:
| | 2023 | | | 2022 | | | 2021 | |
Numerator | | | | | | | | | |
Net loss attributable to common shareholders and used in computation of basic and diluted loss per share | $ | (2,691,670 | ) | $ | (2,287,095 | ) | $ | (1,012,978 | ) |
| | | | | | | | | |
Denominator | | | | | | | | | |
Weighted average number of common shares for computation of basic and diluted loss per share | | 490,310,376 | | | 451,177,796 | | | 422,613,046 | |
For the years ended October 31, 2023, 2022 and 2021, all stock options and conversion features were anti-dilutive and, therefore, are excluded from the calculation of diluted loss per share.
15. Income taxes
(a) The reconciliation of income tax attributed to continuing operations computed at the statutory tax rates to income tax expense is as follows:
| | 2023 | | | 2022 | | | 2021 | |
| | | | | | | | | |
Loss before income taxes | $ | (2,691,670 | ) | $ | (2,287,095 | ) | $ | (1,012,978 | ) |
| | 26.5% | | | 26.5% | | | 26.5% | |
Expected income tax recovery | $ | (713,293 | ) | $ | (606,080 | ) | $ | (268,439 | ) |
Accretion expense and loss (gain) on convertible debentures and derivative liabilities | | 283,688 | | | 269,531 | | | (97,480 | ) |
Stock-based compensation | | 57,761 | | | 10,992 | | | 95,412 | |
Non-deductible (non-taxable) expenses and other items | | (13,660 | ) | | (3,780 | ) | | 82,530 | |
Effect of changes in exchange rates | | 74,714 | | | 940,577 | | | (644,649 | ) |
Change in deferred tax assets not recognized | | 310,790 | | | (611,240 | ) | | 832,626 | |
| $ | - | | $ | - | | $ | - | |
(b) Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:
| | 2023 | | | 2022 | | | 2021 | |
| | | | | | | | | |
Non-capital losses | $ | 8,833,940 | | $ | 8,485,255 | | $ | 8,924,982 | |
| | 159,671 | | | 162,275 | | | 178,808 | |
Property, equipment, patents and deferred costs | | 1,605,743 | | | 1,639,306 | | | 1,794,285 | |
| $ | 10,599,354 | | $ | 10,286,836 | | $ | 10,898,075 | |
Deferred tax asset not recognized | | (10,599,354 | ) | | (10,286,836 | ) | | (10,898,075 | ) |
| $ | - | | $ | - | | $ | - | |
As at October 31, 2023 and 2022, the Company assessed that it is not probable that sufficient taxable profit will be available to use deferred income tax assets based on operating losses in prior years; therefore, there are no balances carried in the consolidated statements of financial position for such assets.
(c) The Company has non-capital losses of approximately $33 million available to reduce future taxable income, the benefit of which has not been recognized in these consolidated financial statements. As at October 31, 2023, the tax losses expire as follows:
| | Canada | | | United States | | | Total | |
| | | | | | | | | |
2026 | $ | 1,731,988 | | $ | - | | $ | 1,731,988 | |
2027 | | 1,456,466 | | | - | | | 1,456,466 | |
2028 | | - | | | - | | | - | |
2029 | | 1,492,685 | | | 143,721 | | | 1,636,406 | |
2030 | | 2,014,021 | | | 1,880,897 | | | 3,894,918 | |
2031 | | 1,213,385 | | | 18,526 | | | 1,231,911 | |
2032 | | 1,344,746 | | | 325,793 | | | 1,670,539 | |
2033 | | 1,629,964 | | | 157,463 | | | 1,787,427 | |
2034 | | 2,358,006 | | | 679,089 | | | 3,037,095 | |
2035 | | 2,664,751 | | | 570,901 | | | 3,235,652 | |
2036 | | 3,127,236 | | | 441,019 | | | 3,568,255 | |
2037 | | 2,503,443 | | | 232,714 | | | 2,736,157 | |
2038 | | 1,692,420 | | | 317 | | | 1,692,737 | |
2039 | | 1,513,943 | | | - | | | 1,513,943 | |
2040 | | 509,976 | | | - | | | 509,976 | |
2041 | | 883,620 | | | - | | | 883,620 | |
2042 | | 1,254,159 | | | - | | | 1,254,159 | |
2043 | | 1,494,374 | | | - | | | 1,494,374 | |
| $ | 28,885,183 | | $ | 4,450,440 | | $ | 33,335,623 | |
(d) In addition, the Company has available capital loss carryforwards of approximately $1.2 million to reduce future taxable capital gains, the benefit of which has not been recognized in these consolidated financial statements. Capital losses carry forward indefinitely.
16. Operating expenses
(a) General and administration
The components of general and administration expenses are as follows:
| Notes | | | 2023 | | | 2022 | | | 2021 | |
General and administration | | | $ | 70,584 | | $ | 59,938 | | $ | 86,186 | |
Rent and occupancy | 8 (b) | | | 17,663 | | | 50,907 | | | 15,536 | |
Office insurance | | | | 1,930 | | | 1,696 | | | 753 | |
Investor relations, listing and filing fees | | | | 52,756 | | | 64,769 | | | 53,029 | |
Telephone | | | | 5,683 | | | 8,056 | | | - | |
| | | $ | 148,616 | | $ | 185,366 | | $ | 155,504 | |
(i) Rent subsidy
The Government of Canada announced the Canada Emergency Rent Subsidy (CERS) to support eligible businesses by covering part of their commercial rent or property expenses. For the year ended October 31, 2023, the Company recognized $nil (2022 - $nil, 2021 - $38,440 CDN ($30,613 USD)) of rent subsidy under this program, which has been recorded as a reduction of rent and occupancy expenses in the consolidated statements of operations and comprehensive loss. This program ran from September 27, 2020 to October 23, 2021.
(b) Professional, other fees and salaries
The components of professional, other fees and salaries expenses are as follows:
| | 2023 | | | 2022 | | | 2021 | |
Professional fees | $ | 144,244 | | $ | 110,933 | | $ | 107,554 | |
Consulting fees | | 67,664 | | | 69,563 | | | 132,793 | |
Salaries and benefits | | 398,144 | | | 467,214 | | | 184,138 | |
| $ | 610,052 | | $ | 647,710 | | $ | 424,485 | |
(i) Wage subsidy
The Canada Emergency Wage Subsidy (CEWS) was announced by the Government of Canada on March 27, 2020 to enable companies negatively impacted by COVID-19 to re-hire workers. Under this program, qualifying business can receive a subsidy for a portion of their employees' wages. For the year ended October 31, 2023, the Company recognized $nil (2022 - $nil, 2021 - $167,388 CDN ($133,699 USD)) of wage subsidy under this program, which has been recorded as a reduction of salaries expenses in the consolidated statements of operations and comprehensive loss. This program concluded on October 23, 2021.
17. Supplemental cash flow information
The following provides a reconciliation of the cash flows from convertible debentures and derivative liabilities :
| | Years ended October 31, | |
| | 2023 | | | 2022 | | | 2021 | |
Balance - beginning of year | $ | 4,433,363 | | $ | 3,239,483 | | $ | 3,615,080 | |
Cash flows from financing activities: | | | | | | | | | |
Proceeds from issuance of convertible debentures | | 645,151 | | | 765,671 | | | 510,000 | |
Repayments of convertible debentures | | (270,000 | ) | | (63,490 | ) | | (593,301 | ) |
Non-cash changes: | | | | | | | | | |
Accretion expense | | 279,834 | | | 1,179,603 | | | 1,169,921 | |
Accrued interest on convertible debentures | | 471,596 | | | 368,280 | | | 408,543 | |
Loss (gain) on repayment of convertible debentures | | 27,243 | | | (47,877 | ) | | - | |
Loss on conversion of convertible debentures | | 21,120 | | | 94,326 | | | - | |
Gain on revaluation of derivative liabilities | | (658,503 | ) | | (409,607 | ) | | (2,547,192 | ) |
Loss on extinguishment of debt | | 1,400,823 | | | 200,650 | | | 1,018,928 | |
Convertible debentures converted into common shares | | (1,656,422 | ) | | (764,432 | ) | | (521,136 | ) |
Renewal of convertible debentures | | - | | | - | | | (16,804 | ) |
Foreign exchange (gain) loss | | (66,753 | ) | | (129,244 | ) | | 195,444 | |
Balance - end of year | $ | 4,627,452 | | $ | 4,433,363 | | $ | 3,239,483 | |
18. Key management compensation and related party transactions
The Company reports the following related party transactions:
(a) Key management compensation
Key management personnel are persons responsible for planning, directing and controlling activities of the Company, including officers and directors. Compensation paid or payable to these individuals (or companies controlled by such individuals) is summarized as follows:
| | 2023 | | | 2022 | | | 2021 | |
Professional, other fees, and salaries | $ | 214,914 | | $ | 133,517 | | $ | 107,201 | |
Stock-based compensation | | 82,946 | | | - | | | 227,500 | |
| $ | 297,860 | | $ | 133,517 | | $ | 334,701 | |
During the year ended October 31, 2023, key management were awarded 1,340,000 options as part of the total 3,000,000 issued (October 31, 2022 - nil). During the year ended October 31, 2021, the Company awarded 5,000,000 stock options to key management as part of the total 9,500,000 stock options issued.
(b) Trade payables and other liabilities
In 2021, the Company reversed certain amounts totalling $422,982 due to the payables being statute barred. These balances carried forward from prior years and the Company derecognized these balances during the year ended October 31, 2021.
Included in accounts payable at October 31, 2023 is $nil payable to a corporation controlled by an officer of the Company (2022 - $5,650 CAD (USD - $4,139)). In addition, at October 31, 2023, accounts payable includes $2,173 payable to a director (2022 - $nil).
19. Commitments and Contingencies
(a) The Company has agreed to indemnify its directors and officers and certain of its employees in accordance with the Company's by-laws. The Company maintains insurance policies that may provide coverage against certain claims.
(b) The Company has previously reported on the lawsuit filed by Mr. Steven Van Fleet against Micromem, the Company’s response to the lawsuit and its counterclaims against Mr. Van Fleet.
On April 29, 2021 the matter was resolved in Micromem’s favor when the Court dismissed Mr. Van Fleet’s claims and ruled that he was liable to the Company and to MAST on their counterclaims. On June 16, 2021, the Court ruled that Micromem and MAST had established damages totaling $765,579 representing the full amount that had been requested; furthermore, the Court awarded costs and statutory prejudgment interest from May 9, 2017. On June 29, 2021 the Court entered a judgement in favor of Micromem and MAST for a total amount of $1,051,739.
With respect to the Company's efforts to collect on that Judgement, a settlement ("Settlement") was reached during October 2021. Pursuant to the Settlement, the Company received an initial one-time payment and is entitled to additional monthly payments over a period of up to six years. The Company will record those payments as and when they are received. The total amount to be received by the Company if Mr. Van Fleet makes all the required payments under the terms of the Settlement will be less than the amount of the Judgement obtained by the Company, but if Mr. Van Fleet does not comply with the terms of the Settlement, it also provides the Company a means of enforcing a larger judgement against Mr. Van Fleet that is substantially in line with the Judgement. Mr. Van Fleet has made the prescribed monthly payments each month since October 2021.
The Company reports the recovery of this contingent asset as funds are received. In the year ended October 31, 2023 the Company has recorded a recovery of $23,555 as a reduction of legal expenses (October 31, 2022 - $9,040, October 31, 2021 - $40,000). At October 31, 2023, $11,705 of the recovery is recorded as other receivable on the consolidated statement of financial position (2022 - $nil).
(c) On November 1, 2023, a former employee filed a statement of claim against the Company relating to employment termination without reasonable notice. The Company filed a statement of defence and counterclaim on November 29, 2023 denying all liability to the former employee. The Company considers the claim of the former employee to be largely and likely without merit and therefore, no provision has been recorded in these consolidated financial statements.
19. Commitments and Contingencies (continued)
(d) On March 23, 2023, the Company signed a letter of intent (the "LOI") with companies incorporated in Romania (the "Parties") whereby the Parties intend to collaborate for the development of certain hardware equipment (the "Project"). Under the LOI, the Parties will provide full payment for the hardware equipments and the Company will provide all engineering support and expertise as required. At October 31, 2023 a formal agreement relating to the Project has not been executed.
During the year ended October 31, 2023, the Company received total advances of $63,000 from the Parties and has paid $63,000 to a third party for the construction of the hardware equipment. The Company has recorded the total advances as a deposit liability and the third party payments as a prepaid expense on the consolidated statement of financial position.
At October 31, 2023 the Company is committed to a further $63,000 payment related to the construction of the hardware equipment.
20. Financial risk management
(a) Currency risk
Currency risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to currency risk to the extent that it incurs expenses and issues convertible debentures denominated in Canadian dollars (CAD). The Company manages currency risk by monitoring the Canadian dollar position of these monetary financial instruments on a periodic basis throughout the course of the reporting period.
As at October 31, 2023, and October 31, 2022, balances that are denominated in CAD are as follows:
| | As at October 31, | | | As at October 31, | |
| | 2023 | | | 2022 | |
| | CAD | | | CAD | |
Cash | $ | 38,444 | | $ | 15,715 | |
Other receivables | $ | 29,080 | | $ | 13,832 | |
Trade payables and other liabilities | $ | 290,311 | | $ | 393,978 | |
Convertible debentures | $ | 2,544,289 | | $ | 2,810,362 | |
Debenture payable | $ | 52,031 | | $ | 51,500 | |
Derivative liabilities | $ | 1,087,044 | | $ | 601,696 | |
Long-term loan | $ | 60,000 | | $ | 60,000 | |
A 10% strengthening of the US dollar against the CDN dollar would decrease net loss and comprehensive loss by $260,000 as at October 31, 2023 (October 31, 2022 - decrease net loss and comprehensive loss by $257,995). A 10% weakening of the USD against the CDN would have the opposite effect of the same magnitude.
(b) Interest rate risk
Interest rate risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk on its interest-bearing convertible debentures. This exposure is limited due to the short-term nature of the convertible debentures.
(c) Credit risk
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company has exposure to credit risk from its cash and receivables. The maximum exposure to credit risk is the carrying value of these financial assets, which amounted to $43,289 as at October 31, 2023 (October 31, 2022 - $33,227).
The risk for cash is mitigated by holding these balances with with central banks and financial institution counterparties that are highly rated. The Company therefore does not expect any credit losses on its cash.
The risk of credit loss on receivable is substantially mitigated by assessing the credit quality of counterparties, taking into account their financial position, past experience and other factors. Management actively monitors the Company’s exposure to credit risk under its financial instruments, including with respect to other receivables.
20. Financial risk management (continued)
(d) Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. With the exception of the long-term loan, all financial liabilities are due within 1 year as at October 31, 2023.
(i) Trade payables
The following represents an analysis of the maturity of trade payables:
| | As at October 31, | | | As at October 31, | |
| | 2023 | | | 2022 | |
Less than 30 days past billing date | $ | 209,285 | | $ | 287,575 | |
| $ | 209,285 | | $ | 287,575 | |
(ii) Convertible debentures and derivative liabilities
The following represents an analysis of the maturity of the convertible debentures and derivative liabilities:
| | As at October 31, | | | | | | As at October 31, | |
| | 2023 | | | | | | 2022 | |
| | Convertible debentures | | | Debenture payable | | | | | | Convertible debentures | | | Debenture payable | |
Less than three months | $ | 2,451,614 | | $ | 37,509 | | | | | $ | 2,445,107 | | $ | - | |
Three to six months | $ | 1,038,355 | | $ | - | | | | | | 1,235,836 | | | - | |
Six to twelve months | $ | 433,815 | | $ | - | | | | | | 446,635 | | | 38,001 | |
| $ | 3,923,784 | | $ | 37,509 | | | | | $ | 4,127,578 | | $ | 38,001 | |
21. Capital risk management
The Company's objectives when managing capital are to (i) maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders, (ii) ensure it has sufficient cash resources to further develop and market its technologies and (iii) maintain its ongoing operations. The Company defines its capital as its net assets, i.e. total assets less total liabilities. In order to secure the additional capital necessary to pursue these objectives, the Company may attempt to raise additional funds through the issuance of equity or convertible debentures or by securing strategic partners. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the year ended October 31, 2023.
Micromem Technologies Inc. Notes to Consolidated Financial Statements For the years ended October 31, 2023, 2022, and 2021 (Expressed in United States dollars, unless otherwise noted) |
22. Subsequent events
Subsequent to October 31, 2023:
(a) The Company secured four private placements with investors for net proceeds of $113,260 and issued a total of 2,400,000 common shares with no warrants, pursuant to prospectus and registrations set forth in applicable securities law.
(b) The Company secured $137,188 in convertible debentures with issuance dates between November 22, 2023 and January 12, 2024. The convertible debentures have a 12 month term, interest rate of 4% per annum and expiring dates ranging from November 22, 2024 to January 12, 2025. The conversion features become effective six months after initiation date.
(c) On January 1, 2024, the Company secured $79,227 ($109,900 CAD) in a convertible debenture with a 12 month term, interest rate of 12% per annum and expiring on January 11, 2025.
(d) The Company converted $127,704 of convertible debentures and accrued interest through the issuance of 3,780,426 common shares.
(e) The Company repaid $154,391 on two of its convertible debentures, as well as a partial payment of $5,000 on another convertible debenture.
(f) A total of 25,000 stock options expired unexercised on December 15, 2023
(g) The Company extended its convertible debentures, with an original maturity date ranging between November 2, 2023 to January 27, 2024, for an additional 6 months, expiring between May 2, 2024 and July 27, 2024. There were no significant changes to the terms of the convertible debentures as a result of the extension.